These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 28710258)
1. The Evolution and Ecology of Resistance in Cancer Therapy. Gatenby R; Brown J Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28710258 [TBL] [Abstract][Full Text] [Related]
2. The Evolution and Ecology of Resistance in Cancer Therapy. Gatenby RA; Brown JS Cold Spring Harb Perspect Med; 2020 Nov; 10(11):. PubMed ID: 33139405 [TBL] [Abstract][Full Text] [Related]
3. Integrating evolutionary dynamics into cancer therapy. Gatenby RA; Brown JS Nat Rev Clin Oncol; 2020 Nov; 17(11):675-686. PubMed ID: 32699310 [TBL] [Abstract][Full Text] [Related]
4. Optimizing Cancer Treatment Using Game Theory: A Review. Stanková K; Brown JS; Dalton WS; Gatenby RA JAMA Oncol; 2019 Jan; 5(1):96-103. PubMed ID: 30098166 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution. Kim JY; Gatenby RA Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831 [TBL] [Abstract][Full Text] [Related]
6. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies. Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of acquired tumor drug resistance. Aleksakhina SN; Kashyap A; Imyanitov EN Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188310. PubMed ID: 31442474 [TBL] [Abstract][Full Text] [Related]
9. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339 [TBL] [Abstract][Full Text] [Related]
10. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Berns K; Bernards R Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522 [TBL] [Abstract][Full Text] [Related]
12. Long range personalized cancer treatment strategies incorporating evolutionary dynamics. Yeang CH; Beckman RA Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811 [TBL] [Abstract][Full Text] [Related]
13. Evolution of resistance to anti-cancer therapy during general dosing schedules. Foo J; Michor F J Theor Biol; 2010 Mar; 263(2):179-88. PubMed ID: 20004211 [TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
15. The multi-factorial nature of clinical multidrug resistance in cancer. Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396 [TBL] [Abstract][Full Text] [Related]
16. Evolution of resistance to cancer therapy. Michor F; Nowak MA; Iwasa Y Curr Pharm Des; 2006; 12(3):261-71. PubMed ID: 16454743 [TBL] [Abstract][Full Text] [Related]
17. Successes and limitations of targeted cancer therapy in lung cancer. Suda K; Mitsudomi T Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapy: overcoming drug resistance with clinical cancer genome. Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399 [No Abstract] [Full Text] [Related]
19. Emergence and prevention of resistance against small molecule inhibitors. Wodarz D; Komarova NL Semin Cancer Biol; 2005 Dec; 15(6):506-14. PubMed ID: 16154360 [TBL] [Abstract][Full Text] [Related]